SCHEMBL3302007

SCHEMBL3302007

Fc1nc(NCc2cccnc2)c2[nH]cnc2n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 2/20 0.54
PDE4A P27815 2/20 0.54
PDE4B Q07343 2/20 0.54
PDE4C Q08493 2/20 0.54
PDE4D Q08499 2/20 0.54
TMIGD3 P0DMS9 2/20 0.50
HTR2B P41595 2/20 0.50
HTR2C P28335 1/20 0.50
USP1 O94782 1/20 0.49
WDR48 Q8TAF3 1/20 0.49
AURKA O14965 1/20 0.48
DAPK3 O43293 1/20 0.48
JAK2 O60674 1/20 0.48
PRKD3 O94806 1/20 0.48
MAP4K4 O95819 1/20 0.48
PAK4 O96013 1/20 0.48
ABL1 P00519 1/20 0.48
LCK P06239 1/20 0.48
CSF1R P07333 1/20 0.48
RET P07949 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5997042 0.86 CDK1 (0.71) CDK1PDE4APDE4BPDE4CPDE4D
SCHEMBL3302002 0.81 MEN1 (0.47) PDE4APDE4BPDE4CPDE4DCLK4
SCHEMBL29060900 0.80 STAT3 (0.65) CDK1PDE4APDE4BPDE4CPDE4D
SCHEMBL30101022 0.77 PDE9A (0.54)
SCHEMBL16146349 0.74 SMN1; SMN2 (0.74) CDK1PDE4APDE4BPDE4CPDE4D
SCHEMBL28004888 0.73 ADORA3 (0.52) CDK1PDE4APDE4BPDE4CPDE4D
SCHEMBL16146710 0.71 CDK1 (0.73) CDK1PDE4APDE4BPDE4CPDE4D
SCHEMBL16146108 0.71 HTT (0.61) PRKACACYP1A2LMNACYP2D6ADORA3
SCHEMBL8009114 0.70 CDK1 (0.71) CDK1PDE4APDE4BPDE4CPDE4D
SCHEMBL16146644 0.70 CDK1 (0.71) CDK1PDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8592581-B2 Trisubstituted purine derivatives CYCLACEL LIMITED (GB) 2013-11-26 US disclosed
EP-2139893-B1 2,6,9-SUBSTITUTED PURINE DERIVATIVES HAVING ANTIPROLIFERATIVE PROPERTIES CYCLACEL LTD (GB) 2013-06-19 EP disclosed
US-20100093769-A1 COMPOUNDS CYCLACEL LIMITED (GB) 2010-04-15 US disclosed
EP-2139893-A2 2,6,9-SUBSTITUTED PURINE DERIVATIVES HAVING ANTIPROLIFERATIVE PROPERTIES Cyclacel Limited (GB) 2010-01-06 EP disclosed
WO-2008122767-A2 2, 6, 9-SUBSTITUTED PURINE DERIVATIVES HAVING ANTI PROLIFERATIVE PROPERTIES CYCLACEL LIMITED (GB) 2008-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093769-A1 COMPOUNDS CCR9, NPY1R, BCL9 CDK1 512/4885PDE4A 2956/4885PDE4B 2665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.